Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Receivables - Net for 3 consecutive years, with $82.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 18.9% to $82.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.4 million, a 18.9% increase, with the full-year FY2025 number at $82.4 million, up 18.9% from a year prior.
  • Receivables - Net was $82.4 million for Q4 2025 at Iovance Biotherapeutics, up from $66.8 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $82.4 million in Q4 2025 to a low of $33000.0 in Q2 2023.
  • A 3-year average of $43.7 million and a median of $57.9 million in 2024 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 95669.7% in 2024, then rose 18.9% in 2025.
  • Iovance Biotherapeutics' Receivables - Net stood at $151000.0 in 2023, then skyrocketed by 45820.53% to $69.3 million in 2024, then grew by 18.9% to $82.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Receivables - Net are $82.4 million (Q4 2025), $66.8 million (Q3 2025), and $59.9 million (Q2 2025).